In October, the U.S. Food and Drug Administration approved Ivermectin, marketed as Sklice, to treat headlice. Over-the-counter availability of this product greatly increases treatment options for head lice. Offering treatment without requiring a doctor’s visit or prescription will help limit this highly contagious parasite spread.
Sklice is a simple, one-dose treatment and is suitable for ages six months and older, with a bodyweight of at least 30 lbs. All pediculicides are not recommended for pregnant or nursing mothers or children less than 30 lbs.
Apply to dry scalp and hair thoroughly and let sit for 10 minutes. Then shampoo out and rinse thoroughly. The American Academy of Pediatrics recommends rinsing lice products off with warm water to minimize unnecessary topical absorption.
This medication is generally well tolerated with minimal side effects; burning or tingling sensations are the most common side effects. When applying this product, use extreme caution around the eyes. Additionally, patients should wash all items touched by someone with lice in hot water, such as clothing, bedding, towels, etc.
According to the CDC, a single lice treatment, such as Sklice, should not be used more than two or three times if it appears ineffective due to parasitical resistance. Switching to another topical pediculicide such as pyrethrins, permethrin, malathion, benzyl alcohol, or spinosad may be necessary. Improper use of the treatment is the leading cause of therapeutic failure.